{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T09:02:00Z","timestamp":1782205320746,"version":"3.54.5"},"reference-count":90,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000038","name":"Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012479","name":"Weston Brain Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson's Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009307","name":"Parkinson Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009307","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000156","name":"Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Neurobiology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.conb.2025.103164","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T08:02:59Z","timestamp":1768982579000},"page":"103164","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["The challenges of experimental pharmacology in identifying novel treatments for Parkinson's disease"],"prefix":"10.1016","volume":"97","author":[{"given":"Margaux","family":"Teil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5464-8334","authenticated-orcid":false,"given":"Philippe","family":"Huot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.conb.2025.103164_bib1","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","article-title":"Parkinson's disease","volume":"386","author":"Kalia","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.conb.2025.103164_bib2","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1001\/jama.2014.3654","article-title":"Pharmacological treatment of Parkinson disease: a review","volume":"311","author":"Connolly","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.conb.2025.103164_bib3","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/mds.20324","article-title":"Sydney multicenter study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years","volume":"20","author":"Hely","year":"2005","journal-title":"Mov Disord"},{"key":"10.1016\/j.conb.2025.103164_sref4","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1002\/mds.30007","article-title":"International Parkinson and movement disorder society viewpoint on biological frameworks of Parkinson's disease: current status and future directions","volume":"39","author":"Kalia","year":"2024","journal-title":"Mov Disord"},{"key":"10.1016\/j.conb.2025.103164_sref5","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3233\/JPD-202481","article-title":"The alpha-Synuclein origin and connectome model (SOC model) of Parkinson's disease: explaining motor asymmetry, non-motor phenotypes, and cognitive decline","volume":"11","author":"Borghammer","year":"2021","journal-title":"J Parkinsons Dis"},{"issue":"Suppl 3","key":"10.1016\/j.conb.2025.103164_bib6","doi-asserted-by":"crossref","first-page":"S497","DOI":"10.1002\/mds.22028","article-title":"The history of dopamine and levodopa in the treatment of Parkinson's disease","volume":"23","author":"Fahn","year":"2008","journal-title":"Mov Disord"},{"key":"10.1016\/j.conb.2025.103164_bib7","article-title":"Continuous subcutaneous foslevodopa\/foscarbidopa infusion for the treatment of motor fluctuations in Parkinson's disease: considerations for initiation and maintenance","volume":"10","author":"Fung","year":"2024","journal-title":"Clin Park Relat Disord"},{"key":"10.1016\/j.conb.2025.103164_bib8","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1007\/s12325-021-01747-1","article-title":"The long-term impact of Levodopa\/Carbidopa intestinal gel on 'Off'-time in patients with advanced Parkinson's disease: a systematic review","volume":"38","author":"Antonini","year":"2021","journal-title":"Adv Ther"},{"key":"10.1016\/j.conb.2025.103164_bib9","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1474-4422(21)00249-0","article-title":"Amantadine in the treatment of Parkinson's disease and other movement disorders","volume":"20","author":"Rascol","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.conb.2025.103164_bib10","doi-asserted-by":"crossref","first-page":"6729","DOI":"10.1007\/s00415-024-12614-8","article-title":"Opicapone for the treatment of early wearing-off in levodopa-treated Parkinson's disease: pooled analysis of patient level data from two randomized open-label studies","volume":"271","author":"Ferreira","year":"2024","journal-title":"J Neurol"},{"key":"10.1016\/j.conb.2025.103164_bib11","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/nrneurol.2010.158","article-title":"Parkinson disease: adjunctive entacapone therapy increases risk of dyskinesia","volume":"6","author":"Sampaio","year":"2010","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.conb.2025.103164_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fddsv.2023.1201419","article-title":"Drug discovery and development: introduction to the general public and patient groups","volume":"3","author":"Singh","year":"2023","journal-title":"Front Drug Discov"},{"key":"10.1016\/j.conb.2025.103164_bib13","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s00213-021-05838-3","article-title":"Challenges in CNS drug development and the role of imaging","volume":"238","author":"Howes","year":"2021","journal-title":"Psychopharmacology"},{"issue":"Pt 7","key":"10.1016\/j.conb.2025.103164_bib14","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1093\/brain\/awm082","article-title":"Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats","volume":"130","author":"Carta","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.conb.2025.103164_bib15","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.pneurobio.2011.08.004","article-title":"The serotonergic system in Parkinson's disease","volume":"95","author":"Huot","year":"2011","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.conb.2025.103164_bib16","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.bbr.2007.01.013","article-title":"Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model","volume":"179","author":"Dekundy","year":"2007","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.conb.2025.103164_bib17","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.parkreldis.2008.11.001","article-title":"Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys","volume":"15","author":"Gregoire","year":"2009","journal-title":"Parkinsonism Relat Disorders"},{"key":"10.1016\/j.conb.2025.103164_sref18","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/mds.29713","article-title":"Buspirone and zolmitriptan combination for Dyskinesia: a randomized, controlled, crossover study","volume":"39","author":"LeWitt","year":"2024","journal-title":"Mov Disord"},{"key":"10.1016\/j.conb.2025.103164_bib19","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.expneurol.2015.05.021","article-title":"NLX-112, a novel 5-HT1A receptor agonist for the treatment of L-DOPA-induced dyskinesia: behavioral and neurochemical profile in rat","volume":"271","author":"Iderberg","year":"2015","journal-title":"Exp Neurol"},{"key":"10.1016\/j.conb.2025.103164_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.107997","article-title":"The selective 5-HT(1A) receptor agonist, NLX-112, exerts anti-dyskinetic and anti-parkinsonian-like effects in MPTP-treated marmosets","volume":"167","author":"Fisher","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.conb.2025.103164_bib21","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.parkreldis.2020.08.009","article-title":"The selective 5-HT1A receptor agonist, NLX-112, exerts anti-dyskinetic effects in MPTP-treated macaques","volume":"78","author":"Depoortere","year":"2020","journal-title":"Parkinsonism Relat Disorders"},{"key":"10.1016\/j.conb.2025.103164_sref22","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1002\/mds.30175","article-title":"NLX-112 randomized phase 2A trial: safety, tolerability, anti-dyskinetic, and anti-parkinsonian efficacy","volume":"40","author":"Svenningsson","year":"2025","journal-title":"Mov Disord"},{"key":"10.1016\/j.conb.2025.103164_bib23","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1124\/jpet.119.264226","article-title":"Preclinical pharmacology of [2-(3-Fluoro-5-Methanesulfonyl-phenoxy)Ethyl](Propyl)amine (IRL790), a novel dopamine transmission modulator for the treatment of motor and psychiatric complications in parkinson disease","volume":"374","author":"Waters","year":"2020","journal-title":"J Pharmacol Exp Therapeut"},{"key":"10.1016\/j.conb.2025.103164_bib24","doi-asserted-by":"crossref","DOI":"10.1111\/ejn.70032","article-title":"Neurophysiological treatment effects of mesdopetam, pimavanserin and amantadine in a rodent model of levodopa-induced dyskinesia","volume":"61","author":"Ronaghi","year":"2025","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.conb.2025.103164_bib25","article-title":"IRL790 modulated striatal D1 neurons synaptic plasticity ameliorating levodopa-induced dyskinesia in mouse","volume":"16","author":"Wang","year":"2024","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/j.conb.2025.103164_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2024.e00334","article-title":"Neurophysiological treatment effects of mesdopetam, pimavanserin and clozapine in a rodent model of Parkinson's disease psychosis","volume":"21","author":"Stan","year":"2024","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.conb.2025.103164_bib27","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41531-018-0071-3","article-title":"Safety and tolerability of IRL790 in Parkinson's disease with levodopa-induced dyskinesia-a phase 1b trial","volume":"4","author":"Svenningsson","year":"2018","journal-title":"NPJ Parkinsons Dis"},{"key":"10.1016\/j.conb.2025.103164_sref28","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/mdc3.70004","article-title":"Mesdopetam for the treatment of levodopa induced dyskinesia in Parkinson's disease: a randomized phase 2b trial","volume":"12","author":"Antonini","year":"2025","journal-title":"Mov Disord Clin Pract"},{"key":"10.1016\/j.conb.2025.103164_bib29","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.neuropharm.2018.03.027","article-title":"mGlu4 allosteric modulation for treating Parkinson's disease","volume":"135","author":"Charvin","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.conb.2025.103164_sref30","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1002\/mds.28970","article-title":"A randomized, double-blind, controlled phase II study of foliglurax in Parkinson's disease","volume":"37","author":"Rascol","year":"2022","journal-title":"Mov Disord"},{"key":"10.1016\/j.conb.2025.103164_bib31","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1002\/mds.27462","article-title":"An mGlu4-Positive allosteric modulator alleviates Parkinsonism in Primates","volume":"33","author":"Charvin","year":"2018","journal-title":"Mov Disord"},{"key":"10.1016\/j.conb.2025.103164_bib32","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1080\/13543784.2020.1839047","article-title":"A case study of foliglurax, the first clinical mGluR4 PAM for symptomatic treatment of Parkinson's disease: translational gaps or a failing industry innovation model?","volume":"29","author":"Doller","year":"2020","journal-title":"Expet Opin Invest Drugs"},{"key":"10.1016\/j.conb.2025.103164_bib33","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1124\/mol.117.110114","article-title":"Differential pharmacology and binding of mGlu2 receptor allosteric modulators","volume":"93","author":"O'Brien","year":"2018","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.conb.2025.103164_bib34","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.neuron.2019.03.004","article-title":"Circuit mechanisms of Parkinson's disease","volume":"101","author":"McGregor","year":"2019","journal-title":"Neuron"},{"key":"10.1016\/j.conb.2025.103164_bib35","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/mds.23616","article-title":"AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials","volume":"26","author":"Berg","year":"2011","journal-title":"Mov Disord"},{"key":"10.1016\/j.conb.2025.103164_bib36","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1002\/mds.26585","article-title":"Mavoglurant in Parkinson's patients with l-Dopa-induced dyskinesias: two randomized phase 2 studies","volume":"31","author":"Trenkwalder","year":"2016","journal-title":"Mov Disord"},{"key":"10.1016\/j.conb.2025.103164_bib37","series-title":"l-Dopa-treated parkinsonian monkeys","article-title":"The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist","author":"Gregoire","year":"2011"},{"key":"10.1016\/j.conb.2025.103164_bib38","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1002\/mds.26659","article-title":"A phase 2A trial of the novel mGluR5-Negative allosteric modulator dipraglurant for levodopa-induced dyskinesia in Parkinson's disease","volume":"31","author":"Tison","year":"2016","journal-title":"Mov Disord"},{"key":"10.1016\/j.conb.2025.103164_bib39","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/mds.25920","article-title":"The mGluR5 negative allosteric modulator dipraglurant reduces dyskinesia in the MPTP macaque model","volume":"29","author":"Bezard","year":"2014","journal-title":"Mov Disord"},{"key":"10.1016\/j.conb.2025.103164_bib40","doi-asserted-by":"crossref","DOI":"10.3390\/cells12071004","article-title":"Effect of the metabotropic glutamate receptor type 5 negative allosteric modulator dipraglurant on motor and non-motor symptoms of Parkinson's disease","volume":"12","author":"Epping-Jordan","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.conb.2025.103164_bib41","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1021\/acschemneuro.9b00589","article-title":"D1 agonist improved movement of Parkinsonian nonhuman Primates with limited dyskinesia side effects","volume":"11","author":"Young","year":"2020","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.conb.2025.103164_sref42","doi-asserted-by":"crossref","first-page":"476","DOI":"10.2174\/1871527322666230331121028","article-title":"Rationale and development of tavapadon, a D1\/D5-Selective partial dopamine agonist for the treatment of Parkinson's disease","volume":"23","author":"Bezard","year":"2024","journal-title":"CNS Neurol Disord: Drug Targets"},{"key":"10.1016\/j.conb.2025.103164_bib43","unstructured":"https:\/\/news.abbvie.com\/2024-12-09-AbbVie-Announces-Positive-Topline-Results-for-the-Phase-3-TEMPO-2-Trial-Evaluating-Tavapadon-as-a-Monotherapy-for-Parkinsons-Disease."},{"key":"10.1016\/j.conb.2025.103164_sref44","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1124\/pharmrev.120.000133","article-title":"Therapeutics in the pipeline targeting alpha-Synuclein for Parkinson's disease","volume":"74","author":"Grosso Jasutkar","year":"2022","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.conb.2025.103164_bib45","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1056\/NEJMoa2202867","article-title":"Trial of prasinezumab in early-stage Parkinson's disease","volume":"387","author":"Pagano","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.conb.2025.103164_bib46","article-title":"A phase 2b, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of intravenous prasinezumab in early-stage Parkinson's disease (PADOVA): rationale, design, and baseline data","volume":"132","author":"Nikolcheva","year":"2025","journal-title":"Parkinsonism Relat Disorders"},{"key":"10.1016\/j.conb.2025.103164_bib47","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa2203395","article-title":"Trial of cinpanemab in early Parkinson's disease","volume":"387","author":"Lang","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.conb.2025.103164_bib48","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamaneurol.2018.1487","article-title":"Safety and tolerability of multiple ascending doses of PRX002\/RG7935, an anti-alpha-synuclein monoclonal antibody, in patients with parkinson disease: a randomized clinical trial","volume":"75","author":"Jankovic","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.conb.2025.103164_bib49","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1002\/mds.27738","article-title":"Randomized phase I clinical trial of anti-alpha-synuclein antibody BIIB054","volume":"34","author":"Brys","year":"2019","journal-title":"Mov Disord"},{"key":"10.1016\/j.conb.2025.103164_sref50","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/s41591-024-02886-y","article-title":"Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson's disease","volume":"30","author":"Pagano","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.conb.2025.103164_bib51","series-title":"Roche's phase IIb study of prasinezumab missed primary endpoint, but suggests possible benefit in early-stage Parkinson's disease","author":"Roche","year":"2024"},{"key":"10.1016\/j.conb.2025.103164_bib52","doi-asserted-by":"crossref","first-page":"9441","DOI":"10.1523\/JNEUROSCI.5314-13.2014","article-title":"Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson's disease-like models","volume":"34","author":"Games","year":"2014","journal-title":"J Neurosci"},{"key":"10.1016\/j.conb.2025.103164_bib53","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.ajpath.2012.11.018","article-title":"Axonopathy in an alpha-synuclein transgenic model of Lewy body disease is associated with extensive accumulation of C-terminal-truncated alpha-synuclein","volume":"182","author":"Games","year":"2013","journal-title":"Am J Pathol"},{"key":"10.1016\/j.conb.2025.103164_bib54","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.nbd.2018.10.016","article-title":"Development of an aggregate-selective, human-derived alpha-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson's disease models","volume":"124","author":"Weihofen","year":"2019","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.conb.2025.103164_bib55","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1093\/hmg\/ddt192","article-title":"Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of alpha-synuclein in Parkinson's disease models","volume":"22","author":"Hebron","year":"2013","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.conb.2025.103164_bib56","doi-asserted-by":"crossref","first-page":"259","DOI":"10.4172\/2155-9899.1000259","article-title":"Tyrosine kinase inhibition regulates early systemic immune changes and modulates the neuroimmune response in alpha-Synucleinopathy","volume":"5","author":"Hebron","year":"2014","journal-title":"J Clin Cell Immunol"},{"key":"10.1016\/j.conb.2025.103164_bib57","doi-asserted-by":"crossref","first-page":"4874","DOI":"10.1038\/srep04874","article-title":"The c-Abl inhibitor, nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson's disease","volume":"4","author":"Karuppagounder","year":"2014","journal-title":"Sci Rep"},{"key":"10.1016\/j.conb.2025.103164_bib58","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.470","article-title":"Pharmacokinetics and pharmacodynamics of a single dose nilotinib in individuals with Parkinson's disease","volume":"7","author":"Pagan","year":"2019","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.conb.2025.103164_bib59","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3233\/JPD-160867","article-title":"Nilotinib effects in Parkinson's disease and dementia with Lewy bodies","volume":"6","author":"Pagan","year":"2016","journal-title":"J Parkinsons Dis"},{"key":"10.1016\/j.conb.2025.103164_bib60","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1001\/jamaneurol.2020.4725","article-title":"Efficacy of nilotinib in patients with moderately advanced parkinson disease: a randomized clinical trial","volume":"78","author":"Simuni","year":"2021","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.conb.2025.103164_bib61","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2201910120","article-title":"High-resolution structural information of membrane-bound alpha-synuclein provides insight into the MoA of the anti-parkinson drug UCB0599","volume":"120","author":"Schwarz","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.conb.2025.103164_bib62","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/s41531-023-00552-7","article-title":"In vivo effects of the alpha-synuclein misfolding inhibitor minzasolmin supports clinical development in Parkinson's disease","volume":"9","author":"Price","year":"2023","journal-title":"NPJ Parkinsons Dis"},{"key":"10.1016\/j.conb.2025.103164_bib63","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s11307-023-01878-7","article-title":"Evaluation and application of a PET tracer in preclinical and phase 1 studies to determine the brain biodistribution of minzasolmin (UCB0599)","volume":"26","author":"Mercier","year":"2024","journal-title":"Mol Imag Biol"},{"key":"10.1016\/j.conb.2025.103164_bib64","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1002\/mds.29170","article-title":"Phase 1\/1b studies of UCB0599, an oral inhibitor of alpha-Synuclein misfolding, including a randomized study in Parkinson's disease","volume":"37","author":"Smit","year":"2022","journal-title":"Mov Disord"},{"key":"10.1016\/j.conb.2025.103164_bib65","unstructured":"https:\/\/www.ucb.com\/newsroom\/press-releases\/article\/findings-from-minzasolmin-proof-of-concept-orchestra-study-shape-next-steps-in-ucb-parkinson-s-research-program."},{"issue":"2","key":"10.1016\/j.conb.2025.103164_bib66","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.regpep.2003.10.028","article-title":"Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes","volume":"117","author":"Nielsen","year":"2004","journal-title":"Regul Pept"},{"key":"10.1016\/j.conb.2025.103164_bib67","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1677\/JOE-09-0132","article-title":"Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease","volume":"202","author":"Kim","year":"2009","journal-title":"J Endocrinol"},{"key":"10.1016\/j.conb.2025.103164_bib68","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1073\/pnas.0806720106","article-title":"GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism","volume":"106","author":"Li","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.conb.2025.103164_bib69","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1742-2094-5-19","article-title":"Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease","volume":"5","author":"Harkavyi","year":"2008","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.conb.2025.103164_bib70","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/jnr.21483","article-title":"Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease","volume":"86","author":"Bertilsson","year":"2008","journal-title":"J Neurosci Res"},{"key":"10.1016\/j.conb.2025.103164_bib71","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.amjms.2017.05.002","article-title":"Neuroprotective effects of eexenatide in a rotenone-induced rat model of Parkinson's disease","volume":"354","author":"Aksoy","year":"2017","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.conb.2025.103164_bib72","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/s41591-018-0051-5","article-title":"Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson's disease","volume":"24","author":"Yun","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.conb.2025.103164_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2021.113693","article-title":"An extended release GLP-1 analogue increases alpha-synuclein accumulation in a mouse model of prodromal Parkinson's disease","volume":"341","author":"Bergkvist","year":"2021","journal-title":"Exp Neurol"},{"key":"10.1016\/j.conb.2025.103164_bib74","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1172\/JCI68295","article-title":"Exenatide and the treatment of patients with Parkinson's disease","volume":"123","author":"Aviles-Olmos","year":"2013","journal-title":"J Clin Investig"},{"key":"10.1016\/j.conb.2025.103164_bib75","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3233\/JPD-140364","article-title":"Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease","volume":"4","author":"Aviles-Olmos","year":"2014","journal-title":"J Parkinsons Dis"},{"key":"10.1016\/j.conb.2025.103164_bib76","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","article-title":"Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Athauda","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.conb.2025.103164_bib77","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S0140-6736(24)02808-3","article-title":"Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial","volume":"405","author":"Vijiaratnam","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.conb.2025.103164_bib78","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S1474-4422(23)00378-2","article-title":"Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trial","volume":"23","author":"McGarry","year":"2024","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.conb.2025.103164_bib79","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.neuroscience.2015.06.054","article-title":"Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease","volume":"303","author":"Liu","year":"2015","journal-title":"Neuroscience"},{"key":"10.1016\/j.conb.2025.103164_bib80","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.neuropharm.2018.02.012","article-title":"Two novel dual GLP-1\/GIP receptor agonists are neuroprotective in the MPTP mouse model of Parkinson's disease","volume":"133","author":"Feng","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.conb.2025.103164_bib81","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ejphar.2017.06.029","article-title":"A novel GLP-1\/GIP dual agonist is more effective than liraglutide in reducing inflammation and enhancing GDNF release in the MPTP mouse model of Parkinson's disease","volume":"812","author":"Yuan","year":"2017","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.conb.2025.103164_bib82","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.npep.2018.07.003","article-title":"Neuroprotective effects of the novel GLP-1 long acting analogue semaglutide in the MPTP Parkinson's disease mouse model","volume":"71","author":"Zhang","year":"2018","journal-title":"Neuropeptides"},{"key":"10.1016\/j.conb.2025.103164_bib83","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s10787-017-0331-6","article-title":"Sitagliptin and liraglutide reversed nigrostriatal degeneration of rodent brain in rotenone-induced Parkinson's disease","volume":"25","author":"Badawi","year":"2017","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.conb.2025.103164_bib84","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.brainres.2016.05.038","article-title":"Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease","volume":"1646","author":"Hansen","year":"2016","journal-title":"Brain Res"},{"key":"10.1016\/j.conb.2025.103164_bib85","article-title":"A phase II, randomized, double-blinded, placebo-controlled trial of liraglutide in Parkinson's disease","author":"Hogg","year":"2022","journal-title":"Lancet Preprint"},{"key":"10.1016\/j.conb.2025.103164_bib86","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1056\/NEJMoa2312323","article-title":"Trial of lixisenatide in early Parkinson's disease","volume":"390","author":"Meissner","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.conb.2025.103164_bib87","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1002\/mds.21897","article-title":"Placebo influences on dyskinesia in Parkinson's disease","volume":"23","author":"Goetz","year":"2008","journal-title":"Mov Disord"},{"key":"10.1016\/j.conb.2025.103164_bib88","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/FBP.0000000000000441","article-title":"Classic animal models of Parkinson's disease: a historical perspective","volume":"30","author":"Hamadjida","year":"2019","journal-title":"Behav Pharmacol"},{"key":"10.1016\/j.conb.2025.103164_bib89","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s00702-023-02633-6","article-title":"The brain-first vs. body-first model of Parkinson's disease with comparison to alternative models","volume":"130","author":"Borghammer","year":"2023","journal-title":"J Neural Transm"},{"key":"10.1016\/j.conb.2025.103164_bib90","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s13311-022-01338-0","article-title":"A mouse model to test novel therapeutics for Parkinson's Disease: an Uudate on the Thy1-aSyn (\"line 61\") Mmce","volume":"20","author":"Richter","year":"2023","journal-title":"Neurotherapeutics"}],"container-title":["Current Opinion in Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959438825001953?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959438825001953?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T08:48:34Z","timestamp":1776156514000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959438825001953"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":90,"alternative-id":["S0959438825001953"],"URL":"https:\/\/doi.org\/10.1016\/j.conb.2025.103164","relation":{},"ISSN":["0959-4388"],"issn-type":[{"value":"0959-4388","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The challenges of experimental pharmacology in identifying novel treatments for Parkinson's disease","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Neurobiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.conb.2025.103164","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103164"}}